BackgroundOur objective was to retrospectively analyze the in uence of DE-T1, a type of amino-polysaccharide extracted from dandelions, on the rates of blastocysts obtained and live births in women undergoing IVF-ET treatment. MethodsThis was a retrospective cohort study, conducting a total of 1014 patients over the age of 30, who received IVF treatment at Hanabusa Women's clinic from Aug. 1, 2012 to Feb. 29, 2020. The patients were divided into two groups, based on their own choice regarding DE-T1 supplementation, which is available as over the counter medicine at the Clinic. The two groups' overall rates of blastocysts obtained were compared and the rates of blastocysts obtained in patients with different ages and Anti-Mullerian hormone (AMH) levels were also compared using an Intention-to-treat (ITT) analysis. Among the patients who completed embryo transfers (ET), the live birth rate was compared between the supplementation group and the non-supplementation group using a Chi-squared test. ResultsThe blastocyst obtained rate in the supplementation group was 75.98%, which was signi cantly higher than that of 57.28% in the non-supplementation group (P=2.4×10 9 ). The blastocyst obtained rate across the range of ages in the supplementation group were signi cantly higher than those of the nonsupplementation group (≥30 and <35 years of age: 90.97% vs 74.32%, P=0.001;≥35 and <40 years of age: 82.40% vs 69.79%, P= 0.010; ≥40 and <43 years of age: 72.90% vs 52.11%, P=0.002; ≥43 years of age: 53.29% vs 22.95%, P= 5.7×10 5 ). The blastocyst obtained rate for both AMH levels in the supplementation group were signi cantly higher than those of the non-supplementation group (AMH≤1.1: 56.47% vs 40.44%, P=0.002; AMH> 1.1: 88.48% vs 71.08%, P=2.52×10 7 ). The live birth rate of the supplementation group was signi cantly higher than that of the non-supplementation group (57.53% vs. 40.0%, P=0.045). ConclusionDE-T1 supplementation might be an in uence on improving the blastocyst obtained rate and live birth rates in women receiving IVF-ET treatment. DE-T1 supplementation might be of bene t to women of different ages and AMH levels.
Objective To explore the appropriate duration of Shawkea DE-T1 use, and to provide a basis for the optimization of the Shawkea DE-T1 administration duration for different women. Methods Based on a previous retrospective cohort study, 1,014 patients aged ≥ 30 years who used in vitro fertilization (IVF) for conception at Hanabusa Women’s Clinic, Kobe, Japan, were included in this secondary analysis and were allocated to an Shawkea DE-T1-administration group (n = 712) and a control group (n = 302) based on their use of Shawkea DE-T1. All patients in the two groups received interventions following the guidelines of the Japanese Institution for Standardizing Assisted Reproductive Technology Intervention, and patients in the administration group were provided Shawkea DE-T1 as recommended by the Nutritional Supplement Support Center of Hanabusa Womens Clinic. The blastocyst obtained rate (percentage of patients who produced at least one blastocyst upon in vitro embryo culture relative to all patients in the same group) was compared between the two groups of patients following treatment durations of 1–3 months, 4–6 months, and > 6 months. Analysis was performed on the actual duration of Shawkea DE-T1 administration for all patients who achieved blastocyst in vitro according to their age level (≥ 30 and < 35 years of age; ≥35 and < 40 years; ≥40 and < 43 years; and ≥ 43 years of age). Results After a Shawkea DE-T1 administration of 1–3 months or 4–6 months, the blastocyst obtained rates in the administration group were significantly higher than those of the control group (83.27% vs. 55.31% for 1–3 months, P = 1.02×10− 10; 69.44% vs. 44.44% for 4–6 months, P = 4.70×10− 4), while no significant difference was uncovered between the two groups with > 6 months of administration (73.35% vs. 72.46%, P = 0.76). Analysis of the treatment duration of patients at different age levels who produced blastocysts showed that the treatment duration increased commensurate with patient age: i.e., 65.25% of women ≥ 30 and < 35 years of age achieved blastocyst after a Shawkea DE-T1 administration of 1–3 months; while only 19.75% of women ≥ 43 years of age successfully achieved in vitro development of embryos to blastocyst stage with a Shawkea DE-T1 administration of 1–3 months. Conclusion Shawkea DE-T1 use for 1–3 months and 3–6 months significantly improved the blastocyst obtained rate in women receiving IVF treatment. Appropriate extension of Shawkea DE-T1 administration duration also achieved a better effect in women of advanced reproductive age.
Background Our objective was to retrospectively analyze the influence of DE-T1, a type of amino-polysaccharide extracted from dandelions, on the rates of blastocysts obtained and live births in women undergoing IVF-ET treatment. Methods This was a retrospective cohort study, conducting a total of 1014 patients over the age of 30, who received IVF treatment at Hanabusa Women’s clinic from Aug. 1, 2012 to Feb. 29, 2020. The patients were divided into two groups, based on their own choice regarding DE-T1 supplementation, which is available as over the counter medicine at the Clinic. The two groups’ overall rates of blastocysts obtained were compared and the rates of blastocysts obtained in patients with different ages and Anti-Mullerian hormone (AMH) levels were also compared using an Intention-to-treat (ITT) analysis. Among the patients who completed embryo transfers (ET), the live birth rate was compared between the supplementation group and the non-supplementation group using a Chi-squared test. Results The blastocyst obtained rate in the supplementation group was 75.98%, which was significantly higher than that of 57.28% in the non-supplementation group (P=2.4×109). The blastocyst obtained rate across the range of ages in the supplementation group were significantly higher than those of the non-supplementation group (≥30 and <35 years of age: 90.97% vs 74.32%, P=0.001;≥35 and <40 years of age: 82.40% vs 69.79%, P= 0.010; ≥40 and <43 years of age: 72.90% vs 52.11%, P=0.002; ≥43 years of age: 53.29% vs 22.95%, P= 5.7×105). The blastocyst obtained rate for both AMH levels in the supplementation group were significantly higher than those of the non-supplementation group (AMH≤1.1: 56.47% vs 40.44%, P=0.002; AMH> 1.1: 88.48% vs 71.08%, P=2.52×107). The live birth rate of the supplementation group was significantly higher than that of the non-supplementation group (57.53% vs. 40.0%, P=0.045). Conclusion DE-T1 supplementation might be an influence on improving the blastocyst obtained rate and live birth rates in women receiving IVF-ET treatment. DE-T1 supplementation might be of benefit to women of different ages and AMH levels.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.